Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TPGS-modified liposomal ginger extract is an advanced drug delivery formulation designed to overcome the low bioavailability and poor aqueous solubility of conventional ginger extract. This system utilizes liposomes—phospholipid-based vesicles—modified with D-α-tocopheryl polyethylene glycol succinate (TPGS), a water-soluble derivative of Vitamin E that enhances stability, prevents liposome aggregation, and improves intestinal absorption. The formulation encapsulates the bioactive constituents of ginger, such as gingerols and shogaols, which possess potent anti-inflammatory and antioxidant properties. Preclinical studies in models of ulcerative colitis have demonstrated that this liposomal delivery system significantly reduces mucosal damage and oxidative stress compared to standard ginger extract, suggesting its potential as a therapeutic agent for inflammatory bowel diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TPGS-modified liposomal ginger extract.